Randomized trial of high‐dose interferon‐α‐2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy
暂无分享,去创建一个
M. Imamura | K. Chayama | H. Aikata | Y. Kawakami | S. Takaki | N. Mori | T. Kawaoka | Shoichi Takahashi | Hiromi Saneto
[1] A. Moya,et al. Hepatitis C virus and the controversial role of the interferon sensitivity determining region in the response to interferon treatment , 2008, Journal of medical virology.
[2] Yoshiyuki Suzuki,et al. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b , 2007, Journal of medical virology.
[3] Tara L. Kieffer,et al. Telaprevir and pegylated interferon–alpha‐2a inhibit wild‐type and resistant genotype 1 hepatitis C virus replication in patients , 2007, Hepatology.
[4] Tara L. Kieffer,et al. Antiviral activity of telaprevir (VX‐950) and peginterferon alfa‐2a in patients with hepatitis C , 2007, Hepatology.
[5] Tara L. Kieffer,et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. , 2007, Gastroenterology.
[6] S. Zeuzem,et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. , 2007, Gastroenterology.
[7] Yoshiyuki Suzuki,et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. , 2007, Journal of hepatology.
[8] F. Penin,et al. The nonstructural 5A protein of hepatitis C virus genotype 1b does not contain an interferon sensitivity-determining region. , 2007, The Journal of infectious diseases.
[9] C. Marcantonio,et al. Repression of Interferon Regulatory Factor 1 by Hepatitis C Virus Core Protein Results in Inhibition of Antiviral and Immunomodulatory Genes , 2006, Journal of Virology.
[10] S. Zeuzem,et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. , 2006, Gastroenterology.
[11] Wenyu Lin,et al. Hepatitis C Virus Core Protein Blocks Interferon Signaling by Interaction with the STAT1 SH2 Domain , 2006, Journal of Virology.
[12] R. Andrade,et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. , 2006, Gastroenterology.
[13] L. Messerini,et al. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. , 2006, Gastroenterology.
[14] T. Berg,et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. , 2006, Gastroenterology.
[15] Yoshiyuki Suzuki,et al. Predictive factors of virological non‐response to interferon–ribavirin combination therapy for patients infected with hepatitis C virus of genotype1b and high viral load , 2006, Journal of medical virology.
[16] Yoshiyuki Suzuki,et al. Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 1b High Viral Load and Non-Virological Response to Interferon-Ribavirin Combination Therapy , 2005, Intervirology.
[17] A. Moreau,et al. Mutations within the Hepatitis C Virus Genotype 1b E2-PePHD Domain Do Not Correlate with Treatment Outcome , 2005, Journal of Clinical Microbiology.
[18] P Martus,et al. Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences , 2004, Gut.
[19] H. Van Vlierberghe,et al. Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients. , 2004, Journal of hepatology.
[20] M. Manns,et al. Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C , 2003, Hepatology.
[21] J. Hoofnagle,et al. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin , 2003, Hepatology.
[22] Stanley M. Lemon,et al. Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease , 2003, Science.
[23] L. Terracciano,et al. Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. , 2003, Gastroenterology.
[24] P. Heinrich,et al. IFN‐α antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling‐3 , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[25] Dieter Häussinger,et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.
[26] A. Craxì,et al. Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high‐dose interferon induction , 2002, Journal of viral hepatitis.
[27] C. Datz,et al. Combination of interferon induction therapy and ribavirin in chronic hepatitis C , 2001, Hepatology.
[28] Kenneth Koury,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[29] X. Forns,et al. Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C , 2001, Journal of medical virology.
[30] S. Hadziyannis,et al. Induction interferon therapy in naïve patients with chronic hepatitis C: increased end‐of‐treatment virological responses but absence of long‐term benefit , 2001, Alimentary pharmacology & therapeutics.
[31] K. Chayama,et al. Association of amino acid sequence in the PKR‐eIF2 phosphorylation homology domain and response to interferon therapy , 2000, Hepatology.
[32] H. Conjeevaram,et al. A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis C: pretreatment stratification by viral burden and genotype , 2000, American Journal of Gastroenterology.
[33] S. Polyak,et al. The protein kinase-interacting domain in the hepatitis C virus envelope glycoprotein-2 gene is highly conserved in genotype 1-infected patients treated with interferon. , 2000, The Journal of infectious diseases.
[34] D. R. Taylor,et al. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. , 1999, Science.
[35] K. Chayama,et al. Fluctuations of hepatitis C virus load are not related to amino acid substitutions in hypervariable region 1 and interferon sensitivity determining region , 1999, Journal of medical virology.
[36] S. Yagi,et al. Development of a Simple and Highly Sensitive Enzyme Immunoassay for Hepatitis C Virus Core Antigen , 1999, Journal of Clinical Microbiology.
[37] D. Häussinger,et al. Prognosis of chronic hepatitis c: Results of a large, prospective cohort study , 1998, Hepatology.
[38] William M. Lee,et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.
[39] J. Mullins,et al. Evolution of Hepatitis C Virus Quasispecies in Hypervariable Region 1 and the Putative Interferon Sensitivity-Determining Region during Interferon Therapy and Natural Infection , 1998, Journal of Virology.
[40] M. Katze,et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. , 1997, Virology.
[41] K. Chayama,et al. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity–determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection , 1997, Hepatology.
[42] E. Schiff,et al. Response to higher doses of interferon alfa‐2b in patients with chronic hepatitis C: A randomized multicenter trial , 1996, Hepatology.
[43] N Enomoto,et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. , 1996, The New England journal of medicine.
[44] J. Hoofnagle,et al. Classification of chronic hepatitis: Diagnosis, grading and staging , 1994, Hepatology.
[45] T. Sugimura,et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[46] R. Purcell,et al. Interrelationship of blood transfusion, non‐A, non‐B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus , 1990, Hepatology.